Plus Therapeutics (NASDAQ:CNSY) Shares Up 7.8% – Time to Buy?

Shares of Plus Therapeutics, Inc. (NASDAQ:CNSY) shot up 7.8% during mid-day trading on Friday. The stock traded as high as $1.96 and last traded at $1.93. Approximately 152,089 shares traded hands during trading, a decline of 17% from the average daily volume of 184,277 shares. The stock had previously closed at $1.79.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Weiss Ratings initiated coverage on Plus Therapeutics in a research report on Tuesday, August 4th. They issued a “sell (e+)” rating on the stock. Zacks Research raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Plus Therapeutics Trading Up 7.8%

The firm has a 50-day moving average price of $2.62. The company has a market capitalization of $14.65 million, a PE ratio of -0.57 and a beta of 1.47.

Plus Therapeutics (NASDAQ:CNSY) last announced its quarterly earnings results on Friday, August 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35). The firm had revenue of $0.41 million during the quarter. Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%. On average, equities research analysts anticipate that Plus Therapeutics, Inc. will post -4.40 EPS for the current fiscal year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s lead investigational product is RNL, also known as rhenium-186 nanoliposome, an experimental treatment designed to deliver radiation directly to tumors while limiting exposure to surrounding healthy tissue.

Plus Therapeutics is primarily evaluating RNL in cancers of the central nervous system, including recurrent glioblastoma and leptomeningeal metastases.